Table 1.
Clinical features of patients who underwent tricuspid transcatheter edge-to-edge repair, distinguishing those with optimal post-procedural result from those with suboptimal optimal post-procedural result.
| Clinical Features | Whole Population (n = 25) |
Suboptimal Result (n = 12) |
Optimal Result (n = 13) |
p |
|---|---|---|---|---|
| Age (y) | 71 ± 6 | 81 ± 5 | 77 ± 7 | 0.1 |
| BSA (m2) | 1.78 ± 0.2 | 1.8 ± 0.2 | 1.8 ± 0.2 | 0.6 |
| Gender (M) | 10 (40%) | 4 (33%) | 6 (46%) | 0.4 |
| Hypertension | 16 (64%) | 9 (75%) | 7 (54%) | 0.2 |
| Dyslipidemia | 10 (40) | 5 (42%) | 5 (38%) | 0.6 |
| Diabetes | 1 (4%) | 0 | 1 8(%) | 0.5 |
| NYHA II | 12 (48%) | 6 (50%) | 6 (46%) | 0.9 |
| NYHA III | 13 (52%) | 6 (50%) | 7 (53%) | 0.9 |
| MRAs | 12 (48%) | 6 (50%) | 6 (46%) | 0.6 |
| ACEi-ARBs-ARNI | 11 (44%) | 6 (50%) | 5 (38%) | 0.4 |
| SGLT2i | 5 (20%) | 4 (33%) | 1 (8%) | 0.1 |
| BB | 18 (72%) | 10 (83%) | 8 (61%) | 0.2 |
Abbreviations: BSA—body surface area, NYHA—New York Heart Association, MRA—mineralocorticoid receptor antagonist, ACEi—angiotensin-converting enzyme inhibitor, ARBs—angiotensin receptor blockers, ARNI—angiotensin receptor–neprilysin inhibitor, SGLT2i—sodium–glucose cotransporter 2 inhibitor, BB—beta adrenergic blocker.